No Data
No Data
No Data
No Data
No Data
These Analysts Just Made An Incredible Downgrade To Their Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) EPS Forecasts
The analysts covering Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for
Simply Wall StMay 4 21:03 ET
Why Shijiazhuang Yiling Pharmaceutical's (SZSE:002603) Shaky Earnings Are Just The Beginning Of Its Problems
A lackluster earnings announcement from Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) last week didn't sink the stock price. Our analysis suggests that along with soft profit numbers, in
Simply Wall StMay 3 19:05 ET
Eling Pharmaceutical (002603.SZ) reported 2023 annual results, with net profit of 1,352 billion yuan, a year-on-year decrease of 42.76%
According to the Zhitong Finance App, Eling Pharmaceutical (002603.SZ) released its 2023 annual report, with revenue of 10.318 billion yuan, a year-on-year decrease of 17.67%. Net profit attributable to shareholders of listed companies was 1,352 billion yuan, a year-on-year decrease of 42.76%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1,244 billion yuan, a year-on-year decrease of 45.58%. The basic income per share is 0.8095 yuan, a cash dividend of 3.00 yuan (tax included) is distributed to all shareholders for every 10 shares, 0 bonus shares (tax included), and no share capital is transferred from the Provident Fund.
Zhitong FinanceApr 26 09:02 ET
Is Weakness In Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
It is hard to get excited after looking at Shijiazhuang Yiling Pharmaceutical's (SZSE:002603) recent performance, when its stock has declined 13% over the past three months. But if you pay close att
Simply Wall StApr 18 00:15 ET
Eling Pharmaceutical (002603.SZ): Jinlida granules have not yet conducted clinical studies on “weight loss” indications
Gelonghui, April 10 | Eling Pharmaceutical (002603.SZ) said on an interactive platform that Jinlida granules have not conducted clinical research on “weight loss” indications. In 2015, the “Randomized, double-blind, placebo-controlled, multicenter clinical trial of efficacy and safety of metformin monotherapy patients with type 2 diabetes after administration of Jinrida granules” led by the Chinese Academy of Traditional Chinese Medicine Guanganmen Hospital and the University of Chicago Chinese Medicine Research Office, was published in “Plos One” magazine. The results showed that in diet control, exercise therapy, and dimethylbisubin
Gelonghui FinanceApr 10 05:30 ET
Individual Investors Invested in Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) Copped the Brunt of Last Week's CN¥2.1b Market Cap Decline
Key Insights The considerable ownership by individual investors in Shijiazhuang Yiling Pharmaceutical indicates that they collectively have a greater say in management and business strategy 52% of t
Simply Wall StMar 27 22:30 ET
No Data
No Data